SEC Form 4 · accession 0001562180-16-001812

Sagent Pharmaceuticals, Inc. · SGNT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Feb 25, 2016

Accepted (ET)

Feb 25, 2016 · 5:00 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001369786

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Feb 25, 2016	M	460	$0.00	A	11,970	D
Common Stock	Feb 25, 2016	M	230	$0.00	A	12,200	D
Common Stock^F2	holding	—	—		—	2,000	I	See Footnote
Common Stock^F3	holding	—	—		—	433,770	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Units^F4,F5	—	Feb 25, 2016	M	460	D	—	—	Common Stock	460	1,381	D
Restricted Stock Units^F4,F5	—	Feb 25, 2016	M	230	D	—	—	Common Stock	230	691	D

F1Vesting of restricted stock units.
F2The shares reported are held by Flanagan Family Limited Partnership. Mr. Flanagan is a managing member of E.O. Flanagan LLC, the general partner of Flanagan Family Limited Partnership.
F3The shares reported are held of record by CNF Investments II, LLC. Voting and investment decisions with respect to all shares held by CNF Investments II, LLC are exercised by its managing member, Mr. Flanagan. Accordingly, Mr. Flanagan may be deemed the beneficial owner of such shares.
F4Each restricted stock unit represents a contingent right to receive one share of SGNT common stock.
F5The restricted stock units vest in four equal annual installments beginning on February 25, 2016. Vested shares will generally be delivered to the reporting person within 30 days following the vesting date.